+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 113 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and effects of vedolizumab given as a subcutaneous injection in children and teenagers aged 2 to 17 years who have moderate to severe active ulcerative colitis or Crohns disease. The study aims to understand any medical problems related to the treatment, the time until hospital visits due to bowel inflammation are needed, and the impact on quality of life. This is a phase 3b extension study involving participants from a previous trial who responded well or did not respond to vedolizumab treatment. Participants who responded well in the previous study will continue to receive vedolizumab subcutaneously either via a prefilled syringe with an autoinjector pen or with a needle safety device. Dosage depends on weight, with injections given every two or four weeks for up to 120 weeks or until the treatment becomes commercially available or the study ends. Those who did not respond well or recently used corticosteroids will not receive the drug but will be followed for approximately two years as an observational group. Throughout the study, participants will visit their clinic multiple times for safety monitoring and assessments. Researchers will track adverse events and serious side effects up to 18 weeks after the last dose, as well as other safety events in the observational group. They will also measure the time to major inflammatory bowel disease events and changes in quality of life using questionnaires. The total participation time can be up to two years from the first dose.

Age: 2Years - 17YearsAll GendersPhase 3
47 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
S

Actively Recruiting

Researchers are studying DB-1303BNT323, a biological drug, in a Phase 12a trial to evaluate its safety and tolerability in adults with advanced or metastatic malignant solid tumors that express HER2. The trial focuses on patients whose tumors are refractory to standard treatments or have no available standard options. This first-in-human study includes both a dose-escalation phase to find the maximum tolerated dose and a dose-expansion phase to further assess safety and explore efficacy in selected tumors. Participants receive DB-1303BNT323 intravenously once every three weeks at various dose levels, including a randomized comparison of doses during some expansion cohorts. Additional treatments may include ritonavir or itraconazole to assess drug interactions, and in some cases, DB-1303BNT323 is combined with Pertuzumab. The study is open-label and multicenter, with dosing continuing according to the protocols schedule. During the trial, participants undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and serious adverse events up to about one year post-treatment. Researchers measure tumor response using RECIST 1.1 criteria and evaluate pharmacokinetics and pharmacodynamics. Organ function, heart performance, and life expectancy are also monitored throughout this period. The estimated study completion is in October 2027.

Age: 18Years +All GendersPhase 1Phase 2
102 locations
P

Actively Recruiting

Researchers are evaluating the anti-tumor effects of golidocitinib compared to investigators choice treatments in adults with relapsed or refractory peripheral T-cell lymphoma PTCL. This phase 3, open-label, randomized study includes patients who have confirmed PTCL and have not responded to or tolerated at least one prior systemic therapy. The study focuses on several PTCL subtypes and aims to improve treatment options for this condition. Participants will be randomly assigned to receive either golidocitinib orally once daily in repeated 21-day cycles or one of the investigators choice treatments, which may include chidamide taken orally twice a week or gemcitabine given intravenously on specific days within 28-day cycles. Treatments continue according to protocol with no masking or blinding involved. During the study, participants will be monitored for progression-free survival as the primary outcome, measured from the date of randomization until disease progression or death, over approximately four years. Secondary outcomes like overall survival will also be tracked. Eligibility assessments, compliance with contraceptive requirements, organ function tests, and ongoing safety monitoring will be part of the participant involvement throughout the study duration.

Age: 18Years +All GendersPhase 3
51 locations
R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations
P

Actively Recruiting

Researchers are evaluating ALPS12 in patients with extensive-stage small cell lung cancer in this phase I, open-label, multicenter trial. The study aims to assess the safety, tolerability, how the drug moves through the body, immune response, and early signs of tumor control. The trial includes two parts a dose-escalation phase to find the best dose and an expansion phase to further study the drugs effects. Participants will receive ALPS12 as an intravenous infusion after pretreatment with obinutuzumab, another IV drug. The dose-escalation part focuses on identifying the maximum tolerated dose by monitoring dose-limiting toxicities, while the expansion part evaluates the antitumor activity of ALPS12 at selected doses. Both parts involve careful administration and observation of the drugs. During the study, participants will be monitored closely with safety checks, blood tests, tumor assessments, and immune response measurements. Researchers will track adverse events, drug levels in the body, and tumor response using recognized criteria. The study lasts approximately 42 months from screening to completion or treatment discontinuation, ensuring thorough follow-up and evaluation throughout.

Age: 18Years +All GendersPhase 1
6 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations

1-10 of 113

1